Compare CVX & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVX | MRK |
|---|---|---|
| Founded | 1879 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.8B | 317.8B |
| IPO Year | 1994 | 1994 |
| Metric | CVX | MRK |
|---|---|---|
| Price | $186.97 | $127.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 17 |
| Target Price | ★ $191.80 | $125.59 |
| AVG Volume (30 Days) | 6.7M | ★ 7.3M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.70% | 3.06% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $189,031,000,000.00 | $65,011,000,000.00 |
| Revenue This Year | $18.01 | $3.61 |
| Revenue Next Year | N/A | $5.41 |
| P/E Ratio | $165.71 | ★ N/A |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $146.49 | $76.66 |
| 52 Week High | $214.71 | $130.29 |
| Indicator | CVX | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 63.57 | 57.78 |
| Support Level | $179.63 | $112.68 |
| Resistance Level | $187.90 | $130.29 |
| Average True Range (ATR) | 3.11 | 3.43 |
| MACD | 2.21 | -0.23 |
| Stochastic Oscillator | 94.57 | 62.44 |
Chevron is an integrated energy company with exploration, production, and refining operations worldwide. It is the second-largest oil company in the United States with 2025 worldwide net oil-equivalent production of 3.7 million barrels per day, including 8.5 billion cubic feet per day of natural gas and 2.3 million barrels of liquids per day. Production takes place in North America, South America, Europe, Africa, Asia, and Australia. The company's refining networks arelocated in the United States and Asia, with a total worldwide refining capacity of 1.8 million barrels of oil a day at year-end 2025. Net proved reserves at year-end 2025 stood at 10.6 billion barrels of oil equivalent, consisting of 5.7 billion barrels of liquids and 29.2 trillion cubic feet of natural gas.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).